Comparative Pharmacology
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus MINIPRESS XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus MINIPRESS XL.
ALFUZOSIN HYDROCHLORIDE vs MINIPRESS XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and reduces peripheral vascular resistance via blockade of postsynaptic alpha-1 receptors on vascular smooth muscle.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
Initial: 1 mg orally once daily at bedtime, gradually increased to 2-20 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
2–3 hours in normotensive patients; prolonged to 6–10 hours in hypertension; extended by renal impairment (up to 4–6 hours in creatinine clearance <10 mL/min)
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Renal (primarily as metabolites, ~90% in urine, <10% unchanged), biliary/fecal (~10%)
Category C
Category C
Alpha-1 Blocker
Alpha-1 Blocker